Clinical Trials Directory

Trials / Completed

CompletedNCT04386512

Clinical Epidemiology and Characteristics Of Covid-19 Cases Occurred In A Lymphoma Setting In The First Epidemic Phase (LymphoCov1)

Épidémiologie Clinique et caractéristiques Des Cas de Covid-19 Survenus Dans un Contexte de Lymphome Lors de la première Phase épidémique

Status
Completed
Phase
Study type
Observational
Enrollment
89 (actual)
Sponsor
Versailles Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The main objective of this retrospective clinical epidemiology study is to describe the characteristics of Covid-19 cases requiring hospitalization in adult patients with lymphomas during the initial phase of the epidemic (from 01/03/20 to 30/04/20). The specific objectives are to estimate the frequency of severe forms of Covid-19 and those requiring intensive care hospitalisation, as well as the mortality related to the epidemic among the active file of patients followed for lymphoma at each study site, to investigate whether certain chemotherapy and/or immunotherapy treatments seem to be associated with severe forms or prolonged evolutions of Covid-19, to describe possible atypical clinical forms among the population of patients treated for lymphoma. Translated with www.DeepL.com/Translator (free version)

Detailed description

I Methods : * Multicentric retrospective observational epidemiological study based on the collection of data from patient records. * Selection of voluntary hospital sites in regions with excess mortality during the epidemic phase. * Systematic identification of Covid-19 cases from coding data (PMSI) from the medical information departments which will be compared with the numbers of patients followed for lymphoma in the haematology departments of each site during the 6 months preceding the epidemic, identified through the PMSI. * Establishment of an ad hoc CRF for cases only with collection of clinical data concerning lymphoma and Covid-19 and routine biological data: Cytopenia (and in particular depth of lymphopenia), hypogammaglobulinemia, inflammatory markers. * Estimated total number of sites: 10-15 and number of cases to be collected: 50-60. Translated with www.DeepL.com/Translator (free version)

Conditions

Timeline

Start date
2020-05-15
Primary completion
2020-06-01
Completion
2020-07-15
First posted
2020-05-13
Last updated
2020-08-07

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04386512. Inclusion in this directory is not an endorsement.